This study comprehensively compared the efficacy and safety of the 4-1BB and CD28 co-stimulatory domains of anti-CD19 CAR T-cells in the treatment of B-ALL. This evidence concerns the gene CD19 and precursor B-cell acute lymphoblastic leukemia.